PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the autoinjector device for AJOVY ® ...

Six abstracts to be presented highlighting results of AJOVY preventive treatment in patients with migraine Oral presentation will feature data from the UNITE study showing that AJOVY significantly ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today that the U.S. Food and ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY ® ...

Please provide your email address to receive an email when new articles are posted on . Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and ...

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and adolescents, Teva Pharmaceuticals announced. Fremanezumab can now be used to ...

CINCINNATI (WKRC) - A medication previously available only for adults is now on the market for children to help reduce migraines. Recent research focused on children aged six to 17 and examined a ...

LAS VEGAS -- Fremanezumab (Ajovy) received FDA approval in 2018 for the prevention of episodic and chronic migraine prevention. But the trials supporting approval of the agent, which functions by ...

The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous ...